These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10146972)

  • 1. Roxithromycin versus cefaclor in lower respiratory tract infection: a general practice pharmacoeconomic study.
    Scott WG; Tilyard MW; Dovey SM; Cooper B; Scott HM
    Pharmacoeconomics; 1993 Aug; 4(2):122-30. PubMed ID: 10146972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of roxithromycin versus cefaclor in Australia.
    Scott WG; Cooper BC; Scott HM; Tilyard MW; Dovey SM
    Pharmacoeconomics; 1995 Jan; 7(1):93-4. PubMed ID: 10155297
    [No Abstract]   [Full Text] [Related]  

  • 3. Roxithromycin vs cefaclor.
    Hughes T; Scott WG; Scott HM
    Pharmacoeconomics; 1993 Nov; 4(5):396-8. PubMed ID: 10146876
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study.
    Scott WG; Cooper BC; Scott HM
    Infection; 1995; 23 Suppl 1():S21-4. PubMed ID: 7782111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice.
    Tilyard MW; Dovey SM
    Diagn Microbiol Infect Dis; 1992; 15(4 Suppl):97S-101S. PubMed ID: 1617932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of treatment with roxithromycin in comparison with erythromycin in patients with lower respiratory tract infections.
    Norinder A; Paulsen O; Hjortsberg C
    Scand J Infect Dis; 1997; 29(1):83-6. PubMed ID: 9112304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxithromycin and lower respiratory tract infections.
    Scott WG; Cooper BC; Scott HM; Karalus NC; Garrett J; Lang SD
    N Z Med J; 1994 May; 107(978):208. PubMed ID: 7980759
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacy-enforced outpatient drug treatment protocols: a case study of Medi-Cal restrictions for cefaclor.
    McCombs JS; Nichol MB
    Ann Pharmacother; 1993 Feb; 27(2):155-61. PubMed ID: 8439688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is roxithromycin better than amoxicillin in the treatment of acute lower respiratory tract infections in primary care? A double-blind randomized controlled trial.
    Hopstaken RM; Nelemans P; Stobberingh EE; Muris JW; Rinkens PE; Dinant GJ
    J Fam Pract; 2002 Apr; 51(4):329-36. PubMed ID: 11978255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind study comparing cefaclor and amoxycillin in the treatment of respiratory tract infections in general practice.
    Brodie NH; McGhie RL; O'Hara H; O'Hara J; Rahman MK; Vallé-Jones JC
    Pharmatherapeutica; 1980; 2(7):494-8. PubMed ID: 7010383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections.
    Tatsis G; Tsoukalas G; Boulbasakos G; Platsouka E; Anagnostopoulou M; Pirounaki M; Paniara O; Sioula E; Raptis J; Saroglou G
    J Antimicrob Chemother; 1998 Mar; 41 Suppl B():69-73. PubMed ID: 9579716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin.
    Carbon C; Hotton JM; Pépin LF; Wohlhuter C; Souêtre E; Hardens M; Lozet H; Riviera M
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():151-61. PubMed ID: 8818856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.
    Markham A; Faulds D
    Drugs; 1994 Aug; 48(2):297-326. PubMed ID: 7527329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of roxithromycin in comparison with erythromycin stearate in patients with lower respiratory tract infections.
    Paulsen O; Christensson BA; Hebelka M; Ljungberg B; Nilsson-Ehle I; Nyman L; Svensson R; Tüll P; Varga Z
    Scand J Infect Dis; 1992; 24(2):219-25. PubMed ID: 1641600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical efficacy of cefetamet pivoxil in lower respiratory tract infection.
    Grassi GG
    Drugs; 1994; 47 Suppl 3():35-42. PubMed ID: 7518765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections.
    Schleupner CJ; Anthony WC; Tan J; File TM; Lifland P; Craig W; Vogelman B
    Arch Intern Med; 1988 Feb; 148(2):343-8. PubMed ID: 3277562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open evaluation of the efficacy and safety of the new macrolide roxithromycin in the treatment of lower respiratory tract infections and pneumonia in Nigerian patients.
    Isah AO; Ohaju-Obodo J
    West Afr J Med; 1996; 15(2):111-6. PubMed ID: 8855675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections.
    Marsac JH
    Diagn Microbiol Infect Dis; 1992; 15(4 Suppl):81S-84S. PubMed ID: 1617929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.